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Purpose:  The aim of the present study was to investigate the pharmaceutical and microbial qualities of 
21 different (of various dosage forms) Herbal Medicinal Products (HMPs) sourced from some traditional 
medicine sales outlets and retail pharmacy outlets in south western Nigeria.  
Method: The pharmaceutical qualities evaluated include tablet crushing strength, friability, disintegration 
time; density of the solutions and suspensions; particle size and angle of repose of the 
powders. Phytochemical tests were carried out to assess the class of compounds present in the 
formulations and the microbial quality of the products was also evaluated. 
Results: The results show that twelve (57.1%) of the products had their manufacturing and expiry dates 
stated, nine (42.9%) products have been registered by NAFDAC and ten (47.6%) did not have their 
content stated but had their therapeutic claims indicated on the container. The tablet formulation 
(Product A) showed acceptable crushing strength and friability but failed the test for disintegration time. 
The angle of repose of the powder dosage forms were considerably high showing that the powders were 
highly cohesive and not free flowing. The microbial load of the products varied considerably. Ten 
(47.6%) of the samples were contaminated by E. coli, seven (33%) were contaminated by Salmonella, 
fifteen (71.4%) were contaminated by Staphylococcus aureus and twelve (57.1%) were contaminated by 
fungi. 
Conclusion: There is need for constant monitoring and control of the standards of herbal medicines 
available in the Nigerian market. 
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INTRODUCTION 
 
Herbal medicine, a form of complimentary and 
alternative medicine, is becoming increasingly 
popular in both developing and developed 
countries1. A World Health Organization (WHO) 
survey indicates that about 70-80% of the world 
population particularly in the developing 
countries rely on non-conventional medicines 
mainly of herbal sources in their primary 
healthcare2,3. WHO has described traditional 
medicine as one of the surest means to achieve 
total health care coverage of the world's 
population. In pursuance of its goal of providing 
accessible and culturally acceptable health care 
for the global population, WHO has encouraged 
the rational use of traditional plant based 
medicines by member states and has developed 
technical guidelines for the assessment of herbal 
medicine3,4.  
 
In Nigeria, there appears to be an overwhelming 
increase in the public awareness and usage of 
herbal medicinal products in the treatment 
and/or prevention of diseases. This may not be 
unconnected to the active mass media 
advertisement embarked upon by the producers 
and marketers of the herbal medicinal products 
(HMPs) who have taken the advantage of the 
relatively high cost of the conventional 
pharmaceutical dosage forms, inaccessibility of 
the orthodox medical services to a vast majority 
of people particularly in the rural areas and the 
reservations by the public due to the prevalence 
of fake, substandard or counterfeit drugs in the 
market. These have placed the HMPs as a ready 
alternative to conventional dosage forms in the 
treatment of diseases. With this increased 
usage, the safety, efficacy and quality of these 
medicines have been an important concern for 
health authorities and health professionals. 
Although herbal remedies are often perceived as 
being natural and therefore safe, they are not 
free from adverse effects which may be due to 
factors such as adulteration, substitution, 
contamination, misidentification, lack of 
standardization, incorrect preparation and/or 
dosage, inappropriate labeling and/or 
advertisement5. In contrast to chemically defined 
medicinal products, the biopharmaceutical 
quality and behavior of HMPs are often not well 
documented6. The WHO Good Manufacturing 
Practice Guidelines have provided technical 
guidelines to national regulatory authorities, 
scientific organizations, and manufacturers to 
undertake an assessment of the 
documentation/submission/dossiers in respect of 
herbal medicinal products. In Nigeria, the 
National Agency for Food Drug Administration 
and Control (NAFDAC) is responsible for drug 
administration and control of the quality of 
medicinal products including HMPs generally 
available in the market. 
 
In an attempt to enhance the acceptability of the 
HMPs by consumers, many of the products have 
been formulated into conventional modern 
dosage forms such as tablets, capsules, 
suspensions, solutions and powders. With the 
prevalence in the Nigerian market of these 
products, it would be of great interest to evaluate 
the pharmaceutical qualities of these HMPs, 
irrespective of the medicinal content and 
therapeutic claims. Thus in the present study, 
the pharmaceutical and microbial qualities of 21 
different brands of Herbal Medicinal Products 
(HMPs) sourced from various traditional 
medicine sales outlets and retail pharmacy 
outlets in south western Nigeria have been 
evaluated. Phytochemical tests were done to 
assess the class of compounds in the 
formulations and the microbial content was also 
evaluated. 
 
Materials and methods 
Materials 
The following materials were used: 
Nutrient broth, Nutrient agar, MacConkey agar, 
Salt nutrient agar, Cetrimide Nutrient agar, 
Sabauraud dextrose agar were all obtained from 
Oxoid (Oxoid Products, Basingstoke, UK). 
Twenty one (21) different Herbal Medicinal 
Products (HMPs) were sourced from various 
traditional medicine sales outlets and retail 
pharmacy outlets in south western Nigeria. The 
type of dosage form, manufacture and expiry 
dates and the therapeutic indications are 
presented in Table 1. 
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Table1:   Product code, Dosage form, Content, NAFDAC registration, Country of Origin,  
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Contents  Therapeutic claim  


















No - Heamorrhoids, 
pile. 
M Solution Sept 2004 Sept 
2007 



























Aug 2004 Jul 2007 Nigeria  Yes Alstonia bonei, 
Anthoderta nobilis, 
Pandiaka involucrate, 




















Nigeria Yes  Xylopia aethopica, 
Citrus medica, Var 
acida, Cassia alata, 















Nigeria Yes Alstonia congensis, 











R Powder - - Nigeria No - Heamorrhoids 
S Powder - - Nigeria No - Typhoid fever 
T Powder - - Nigeria No - Diabetes 
U Powder - - Nigeria No - Pile 
  
- = Not stated/available 
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Determination of table/capsule properties: 
Twenty (20) tablets/capsules were weighed 
individually using an electronic balance (Mettler 
PE360 Deltarange, Switzerland) and the mean 
weight was calculated.  
 
The crushing strength of the tablets was 
determined at room temperature using a Pfizer 
hardness tester (Pfizer Inc., Groton, CT). The 
mean crushing strength was calculated. The 
percent friability of the tablets was determined 
using a friabilator (Erweka Apparatebau 
,Germany) operated at 25rpm for 4 min. 
 
The disintegration times, DT, of the 
tablets/capsules were determined in distilled water 
at 37 ±0.5oC using an Erweka disintegration 
tester (Erweka Apparatebau ,Germany). All 
measurements were made in quadruplicate, and 
the results given are the means of four 
determinations. 
 
Determination of powder properties 
The particle size distribution and shape of the 
HMPs in powder dosage form were determined 
by optical microscopy on approximately 300 
particles per sample. 
 
The flow properties of the powders were 
evaluated by measuring the angle of repose. 5g 
of each powder was poured into a cylindrical 
glass fixed to a flat base of diameter 28mm. The 
cylinder was slowly pulled out vertically so as to 
form a cone of powder on the base. The height 
of the cone was measured and the angle of 
repose, θ, was calculated using the equation: 
  
Tan θ = h\ r.....................................(1) 
 
where h is the height of the conical powder 
heap, and r is the radius of the circular base. 
Determinations were done in triplicates. 
 
Determination of solutions properties 
The density of the solutions and suspension 
were determined by measuring the weight of 1ml 
of the sample. The density is taken as the mass 




The following phytochemical tests were carried 
out on the products: Tests for alkaloids was 
performed using Wagner and Dragendoff’s 
reagent7. 0.5 g of the product was added to 5ml 
of 1% aqueous HC1 on a steam bath. This was 
filtered and 1 ml of the filtrate treated with a few 
drops of Draggendorf’s reagent and another 1 ml 
portion treated similarly with Wagner’s reagent. 
The formation of precipitates was an indication 
of the presence of alkaloids. The blood 
heamolysis test was used to tests for Saponins7. 
The test for anthraquinone was done by shaking 
0.5 g of the product with 5 ml of chloroform for 5 
min. The extract was filtered, and the filtrate 
shaken with an equal volume of 10% ammonia 
solution. A pink, violet or red colour in the 
ammoniacal layer (Lower layer) indicated the 
presence of free anthraquinones. The test for 
tannins was done using the ferric chloride test. A 
deep green colouration showed the presence of 
tannins8. The Keller- Kiliani test was used to test 
for the presence of cardenolides7,8. 0.5g of the 
product was dissolved in 2 ml of glacial acetic 
acid containing one drop of ferric chloride 
solution. This was then underlayed with 1 ml of 
concentrated sulphuric acid. A brown ring 
obtained at the interphase indicated the 
presence of a deoxy sugar typical of 
cardenolides8. 
 
Microbial content determination: 
For solid samples i.e. tablets and powders, 1g 
quantities were disintegrated in 9 mL of sterile 
distilled water while for the liquid formulations, 
1ml quantities was dissolved/suspended in 9ml 
of sterile distilled water. Serial dilutions were 
made and viability assessed using the pour plate 
method. The plates were incubated at 37oC for 
24h. The plate was placed on a colony counter 
and the number of colony forming units was 
taken. The microbial content was taken as the 
mean of duplicate determinations. The media 
utilized were Nutrient agar, Cetrimide Nutrient 
agar, Salt Nutrient agar, MacConkey agar. For 
detection of fungal growth in the samples, 
Sabouraud dextrose agar was poured into the 
plate and allowed to set and 1ml aliquot of each 
sample was spread on the surface and the 
plates were incubated at 270C for 72 h. 
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The viable aerobic bacterial count and the viable 
count for moulds (dry surface method) and the 
absence (or presence) of Escherichia coli and 
Staphylococcus aureus were assessed using 
well established methods9,10. 
 
Results and discussion 
The herbal medicinal products selected for this 
study consisted of one (1) tablet, one (1) 
suspension, three (3) capsule, four (4) powders 
and twelve (12) liquid dosage forms. All the 
samples, except for those samples without the 
manufacture or expiry dates indicated, were 
within their shelf life at the time of investigation. 
Twelve (57.1%) of the products had their 
manufacturing and expiry dates stated and only 
nine (42.9%) products have been registered by 
NAFDAC. This is contrary to the prohibition of 
the manufacture, advertisement, sale and 
distribution of herbal medicinal products in 
Nigeria without proper registration by 
NAFDAC11. The European Agency for the 
Evaluation of Medicinal Products, EMEA and 
WHO have stated that the quantity of the herbal 
drug should be given as a range corresponding 
to a defined quantity of constituent with known 
therapeutic activity and if constituent(s) 
responsible for the therapeutic activity are 
unknown, the quantity of the whole herbal drug 
preparation should be given 6,12. Furthermore, 
the dosage form, therapeutic indications and 
expiry dates should be stated. However, ten 
(47.6%) of the products did not have their 
content stated even though their therapeutic 
claims were indicated either on the container or 
in the leaflet insert. 
 
The physicochemical properties of the product 
formulations are presented in Table 2. The 




































A Tablet 548.0+ 0.5 137.2+19.6 0.8+0.0 120.0±3.0 - - - - 
B Capsule  500.0+ 0.5 - - 30.0±4.5 - - - - 
C Capsule  380.0+ 0.3 - - 39.0±2.5 - - - - 
D Capsule  255.0+ 0.3 - - 54.0±4.0 - - - - 
E  Suspen
sion  
- - - - 1.256±0.012 - - - 
F Solution - - - - 1.024±0.023 - - - 
G Solution - - - - 1.010±0.032 - - - 
H  Solution  - - - - 1.017±0.046 - - - 
I  Solution  - - - - 1.019±0.101 - - - 
J  Solution  - - - - 1.037±0.024 - - - 
K  Solution  - - - - 1.006±0.034 - - - 
L Solution - - - - 1.010±0.058 - - - 
M Solution  - - - - 1.012±0.014 - - - 
N  Solution  - - - - 1.002±0.008 - - - 
O  Solution  - - - - 1.039±0.012 - - - 
P  Solution  - - - - 0.990±0.009 - - - 
Q Solution  - - - - 1.037±0.056 - - - 
R Powder - - - - - 215.56±5.90 52.6±1.2 0.232±0.002 
S  Powder - - - - - 2.87±0.98 61.9±2.6 0.427±0.026 
T Powder - - - - - 98.70±2.67 60.0±0.9 0.368±0.042 
U Powder - - - - - 13.38±1.12 66.5±1.8 0.386±0.008 
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tablets ≥250mg may not deviate from the 
average weight by more than 5%w/w and 
capsules of ≥ 300mg may not deviate by more 
than 7.5%w/w13. The results of the weight 
uniformity test for the tablets and capsules were 
within the acceptable pharmacopoeial limits. The 
tablet formulation (Product A) showed 
acceptable crushing strength and friability 
indicating the ability to resist chipping and 
abrasion or breakage under conditions of 
storage, transport and handling. However, the 
tablet had disintegration time of 120 min. This is 
considerably higher than the requirement for 
immediate release tablets (i.e. disintegration 
within 15minutes). This may result in delayed 
release of the active constituent and subsequent 
onset of action. In many cases, a complete and 
rapid disintegration/dissolution of the herbal drug 
preparation for example extracts, from the solid 
oral dosage formulation is a prerequisite for non-
problematic bioavailability and clinical efficacy of 
the HMPs. Some preparations such as lipid 
extracts and essential oils however are not 
easily soluble and do not dissolve completely 
from the pharmaceutical formulation6. Such 
HMPs may require other excipients such as 
disintegrants to aid the release of the active 
constituent from the dosage form. The 
disintegration times of the capsules (Products B 
– D) also varied considerably. Products C and D 
did not pass the pharmacopoeial test for 
disintegration of capsules (i.e. disintegration 
within 30minutes). The weight per mL of the 
solution was used as a means of assessing the 
uniformity of weight per dose of the product 
dispensed. The solutions (Products F - Q) 
generally contained about 1g per mL of the 
solution and the standard deviation showed that 
the variation in weight was generally ≤5%. The 
angle of repose of the powders (Products R - U) 
 
Table 3: Phytochemical analysis of the HMPs  
 
Product code Phytochemical tests 
 Alkaloids Anthraquinones Saponins Tannins cardenolides 
A  + - - + - 
B - + + + + 
C + - + + - 
D - - + - - 
E  + - + - - 
F - - + + + 
G - - + + - 
H - - + + - 
I      
J - + - - - 
K + - - - - 
L + - - - - 
M - - + + - 
N - - + + + 
O - - + - - 
P - - + - + 
Q - - + - + 
R + - - + - 
S - - + + - 
T + - + + + 
U + + + + - 
Key:    - = Absent    
+ =  Present  
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was generally high showing that the powders 
were highly cohesive and are not free-flowing. 
This may result in the non-uniformity of dose 
dispensed from the container during use. 
 
In contrast to orthodox medicinal products, the 
compositions of herbal drug preparations are 
determined by the practitioner, manufacturing 
process, and the intended dosage form herbal 
drug6. The results of the phytochemical tests are 
presented in Table 3. The results showed that 
the products contain alkaloids, anthraquinones, 
tannins, saponins and cardinolides. It is well 
known that HMPs usually consists of more than 
one plant or active constituents and their 
therapeutic efficacy is not provided by a single 
group of compounds. Some of these compounds 
act synergistically to modify the bioavailability 
and efficacy of the active constituent. 
Furthermore, the constituent responsible for the 
claimed therapeutic effects are often unknown or 
only partly explained and thus precludes the 
level of control which could be routinely achieved 
with synthetic drug substances in conventional 
pharmaceuticals6. Moreover, the composition of 
an herbal drug preparation is determined by the 
practitioner who should be able to identify the 
correct plant species. Thus, misidentification of 
the plant is possible and the plants may contain 
potentially toxic constituents. As a result, there is 
 










E.coli Salmonella Pseudmonads 
 
Fungi 
A  - - - - - 4.0 x 103 
B 5.0 x 103 1.4 x 104 7.0 x 103 - - - 
C 7.5 x 103 2.0 x 103 3.0 x 103 - - - 
D 3.0 x 104 7.0 x 103 13.0 x 103 3.0 x 103 - - 
E  2.0 x 104 3.0 x 104 7.0 x 103 1.0 x 103 - 3.0 x 104 
F 1.0 x103 1.0 x103 - - - - 
G 5.0 x 102 - - - - - 
H 5.0 x 103 1.0 x103 - - - - 
I 5.0 x 103 2.0 x 103 1.5 x 102 1.0 x 103 - 2.0 x 103 
J 1.5 x 102 5.0 x 102 - - - - 
K 7.5 x 103 1.0 x 103 - - - - 
L 5.0 x 103 - - - - - 
M - - - - - 3.0 x 103 
N 2.0 x 104 4.0 x 103 1.5 x 104 - - 1.2 x 104 
0 - - - - - 3.5 x 103 
P - - - - - 3.0 x 103 
Q 1.0 x104 5.0 x 103 - - - 3.5 x 103 
R 2.2 x 104 1.2 x104 9.0 x 103 3.0 x 102 - 1.2 x 104 
S 8.0 x 103 6.0 x 103 5.0 x 103 2.0 x 102 - 7.0 x 103 
T 5.0 x 103 3.0 x 103 2.0 x 103 1.5 x 102 - 6.0 x 103 
U 8.0 x 103 2.0 x 103 3.0 x 103 2.0 x 102 - 3.5 x 103 
      
Key: - = No growth  
Cfu/ml = Colony forming unit per ml or g 
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no guarantee of the authenticity and quantity of 
plant material used in the preparations and thus 
the quality of traditional medicines so produced 
varies widely and may not even be effective. 
Furthermore, herbal medicines, particularly 
those grown as cultivated crops have been 
shown to be contaminated by pesticides, 
fumigants, toxic metals and endotoxins13. 
Therefore, there is a need to select proper and 
appropriate technologies for the industrial 
production of traditional medicines such that the 
effectiveness of the preparation is ensured.  
 
Herbal medicinal products usually contain 
bacteria and moulds from soil and atmosphere. 
The limits of microbial contamination are: total 
aerobic bacteria 105cfu/g, yeasts and moulds 103 
cfu/g, Enterobacteria and other Gram negative 
organisms 103cfu/g and E. coli and Salmonella 
should be absent14. The microbial nature and 
content of the microbial contaminant in the 
HMPs are presented in Table 4. The results 
show that the microbial load of the products 
varied considerably. The samples were 
contaminated to varying degrees with bacteria 
and Fungi. Of concern is the level of 
contamination of the products by Gram negative 
organisms which are considered pathogenic. 
While none of the samples contained 
Pseudomonas aeruginosa, which is primarily a 
soil bacterium and the cause of various 
infections, e.g. of burns, and the urinary and 
respiratory tracts, ten (47.6%) of the samples 
were contaminated by E.coli, which is an 
intestinal bacterium and is an indicator for 
contamination by feaces and seven (33%) were 
contaminated with Salmonella. Fifteen (71.4%) 
of the products were contaminated by 
Staphylococcus aureus and twelve (57.1%) were 
contaminated by fungi. Soil, harvesting, drying, 
storage conditions and improper handling 
influence the microbiological quality of herbal 
drugs. The presence of microbial contaminant in 
non sterile pharmaceutical products can reduce 
or even inactivate the therapeutic activity of the 
products and has the potential to adversely 
affect patients taking the medicines15. Some 
infectious outbreaks have been associated with 
the use of heavily contaminated raw materials of 
natural origin16. The microbial quality of 
pharmaceuticals is influenced by the 
environment and quality of the raw materials 
used during formulation. Thus manufacturers 
should ensure the lowest possible level of 
microorganisms in the raw material, finished 
dosage forms and the packaging components to 
maintain appropriate quality, safety and efficacy 
of the products.  
 
The results of the present work show that 
Products A to D, which were among the products 
which did not show acceptable pharmaceutical 
and microbial qualities were expensive, popular, 
widely advertised and used in south western 
Nigeria for the treatment of various conditions. 
There is, therefore, the need for constant 
monitoring and quality control of herbal 
medicinal products manufactured, sold, 
advertised and used in Nigeria. The quality 
requirements for orthodox drug preparations are 
stringent in terms of content of active principles 
and toxic materials. Whereas the production of 
traditional medicines for local use does not 
require such stringent standards, HMPs are 
usually an improved version of the already 
produced medicines using traditional methods. 
As herbal medicinal products are complex 
mixtures which originate from biological sources, 
great efforts are necessary to guarantee a 
constant and adequate quality. By carefully 
selecting the plant material and a standardized 
manufacturing process, the pattern and 
concentration of constituents of herbal medicinal 
products should be kept as constant as possible 
as this is a prerequisite for reproducible 
therapeutic results6. Quality has to be built into 
the whole process beginning from the selection 
of propagation material to the final product 
reaching the consumer. Thus, there is need for 
constant monitoring and control of the standards 
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